Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 21, 2018 Filed Nov 26, 2018 22:36 UTC |
Hollingshead JamesPresident, Americas
|
GrantResMed Common Stock | 28,810 | $104.18 | $3,001,425.80 |
DisclosureSEC source: 0001567619-18-006938 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,085 F1 · shares: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on November 21, 2018, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 20:55 UTC |
McHale RichardPresident, RC Business
|
Tax withholdingResMed Common Stock | 7,137 | $104.18 | $743,532.66 |
DisclosureSEC source: 0001567619-18-006921 · doc1.xml · nonDerivative · entry 2 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,307 F2 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 20:55 UTC |
McHale RichardPresident, RC Business
|
GrantResMed Common Stock | 12,793 | $104.18 | $1,332,774.74 |
DisclosureSEC source: 0001567619-18-006921 · doc1.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,444 F1 · shares: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on November 21, 2018, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:39 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 32,234 | $104.18 | $3,358,138.12 |
DisclosureSEC source: 0001567619-18-006927 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,390 F1 · kind: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on November 21, 2018, when the compensation committee certified that the performance metrics were met. F1 · shares: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on November 21, 2018, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 20:43 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 11,554 | $104.18 | $1,203,695.72 |
DisclosureSEC source: 0001567619-18-006916 · doc1.xml · nonDerivative · entry 2 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,608 F2 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on November 19, 2015. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 20:43 UTC |
Sodhi RajwantPresident, SaaS Business
|
GrantResMed Common Stock | 20,712 | $104.18 | $2,157,776.16 |
DisclosureSEC source: 0001567619-18-006916 · doc1.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,162 F1 · shares: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on November 21, 2018, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 20:20 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 15,453 | $104.18 | $1,609,893.54 |
DisclosureSEC source: 0001567619-18-006911 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,002 F2 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on November 19, 2018. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 20:20 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 27,702 | $104.18 | $2,885,994.36 |
DisclosureSEC source: 0001567619-18-006911 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,455 F1 · shares: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on November 21, 2018, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 20:25 UTC |
McHale RichardPresident, RC Business
|
Tax withholdingResMed Common Stock | 939 | $106.94 | $100,416.66 |
DisclosureSEC source: 0001567619-18-006838 · doc1.xml · nonDerivative · entry 2 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,651 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 20:25 UTC |
McHale RichardPresident, RC Business
|
Tax withholdingResMed Common Stock | 1,149 | $106.94 | $122,874.06 |
DisclosureSEC source: 0001567619-18-006838 · doc1.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,590 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 128.63 shares of ResMed stock purchased on October 31, 2018, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 20:16 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 1,713 | $106.94 | $183,188.22 |
DisclosureSEC source: 0001567619-18-006837 · doc1.xml · nonDerivative · entry 3 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,450 F4 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 20:16 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 1,542 | $106.94 | $164,901.48 |
DisclosureSEC source: 0001567619-18-006837 · doc1.xml · nonDerivative · entry 2 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,163 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 20:16 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 939 | $106.94 | $100,416.66 |
DisclosureSEC source: 0001567619-18-006837 · doc1.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,705 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 110.08 shares of ResMed stock purchased on October 31, 2018, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 16:58 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 3,300 | $104.49 | $344,817.00 |
DisclosureSEC source: 0001567619-18-006729 · doc1.xml · nonDerivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lissette and Michael Farrell Family Foundation Disclosed balance after: 0 Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 16:58 UTC |
Farrell Michael J.Chief Executive Officer
|
GiftResMed Common Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006729 · doc1.xml · nonDerivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lissette and Michael Farrell Family Foundation Disclosed balance after: 3,300 F2 · kind: Represents a gift to the Lisette and Michael Farrell Family Foundation, a 501(c)(3) non-profit corporation. F3 · ownership.nature: Mr. and Mrs. Farrell retain dispositive power over foundation holdings. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 16:58 UTC |
Farrell Michael J.Chief Executive Officer
|
GiftResMed Common Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006729 · doc1.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lissette and Michael Farrell Family Trust Disclosed balance after: 10,340 F2 · kind: Represents a gift to the Lisette and Michael Farrell Family Foundation, a 501(c)(3) non-profit corporation. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 16:58 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 13,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006729 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lissette and Michael Farrell Family Trust Disclosed balance after: 13,640 F1 · kind: Acquisition originates from a maturity distribution of the Charitable Income Trust II to beneficiaries. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:50 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,000 | $101.44 | $202,880.00 |
DisclosureSEC source: 0001567619-18-006573 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,156 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. F2 · balance_after: Includes 134.30 shares of ResMed stock purchased on October 31, 2018, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 20:24 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 3,307 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001567619-18-006626 · doc1.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,372 Underlying: ResMed Commmon Stock · 3,307 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 20:24 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 984 | $101.44 | $99,816.96 |
DisclosureSEC source: 0001567619-18-006626 · doc1.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 109,222 Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 20:24 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 3,307 | $101.44 | $335,462.08 |
DisclosureSEC source: 0001567619-18-006626 · doc1.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,805 Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 20:24 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 3,307 | $43.63 | $144,284.41 |
DisclosureSEC source: 0001567619-18-006626 · doc1.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 01:50 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock Options · Derivative | 22,883 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001567619-18-006573 · doc1.xml · derivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,883 Underlying: ResMed Common Stock · 22,883 shares Expires 2025-11-14 F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2019, 2020 and 2021. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 01:36 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock Options · Derivative | 19,451 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001567619-18-006572 · doc1.xml · derivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,451 Underlying: ResMed Common Stock · 19,451 shares Expires 2025-11-14 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2019, 2020 and 2021. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 01:30 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock Options · Derivative | 80,092 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001567619-18-006571 · doc1.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,092 Underlying: ResMed Common Stock · 80,092 shares Expires 2025-11-14 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2019, 2020 and 2021. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 01:17 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock Options · Derivative | 102,975 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001567619-18-006570 · doc1.xml · derivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,975 Underlying: ResMed Commmon Stock · 102,975 shares Expires 2025-11-14 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2018, 2019 and 2020. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 01:08 UTC |
FARRELL PETER CDirector
|
GrantResMed Common Stock Options · Derivative | 11,442 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001567619-18-006569 · doc1.xml · derivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,442 Underlying: ResMed Common Stock · 11,442 shares Expires 2025-11-14 F2 · derivative.exercise_date: Options vest in full (i) on the first Nov. 11 following the grant date or (ii) the first annual shareholders meeting following grant date. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 00:37 UTC |
WAREHAM JOHN PDirector
|
GrantResMed Common Stock Options · Derivative | 11,442 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001567619-18-006568 · doc1.xml · derivative · entry 2 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,442 Underlying: ResMed Commmon Stock · 11,442 shares Expires 2025-11-14 F1 · derivative.exercise_date: Options vest in full (i) on the first Nov. 11 following the grant date or (ii) the first annual shareholders meeting following grant date. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 00:28 UTC |
TAYLOR RONALD RDirector
|
GrantResMed Common Stock | 2,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006567 · doc1.xml · nonDerivative · entry 1 TAYLOR RONALD R · CIK 0001161920 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,284 F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2019, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 00:23 UTC |
SULPIZIO RICHARDDirector
|
GrantResMed Common Stock | 2,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006566 · doc1.xml · nonDerivative · entry 1 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,953 F1 · shares: Shares awarded are restricted stock units. The RSUs cliff vest on the earlier of November 11, 2019, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 00:04 UTC |
Burt CarolDirector
|
GrantResMed Common Stock | 2,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006561 · doc1.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,173 F1 · shares: Shares awarded are restricted stock units. The RSUs cliff vest on the earlier of November 11, 2019, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 14, 2018 Filed Mar 2, 2019 01:00 UTC |
Drexler KarenDirector
|
GrantResMed Common Stock | 2,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-005859 · doc1.xml · nonDerivative · entry 1 Drexler Karen · CIK 0001504699 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,524 F1 · date: Original filing was rejected for footnote error. Resubmission to correct the administrative error. F2 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2019, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 23:13 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 1,717 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001567619-18-005885 · doc1.xml · derivative · entry 5 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 1,717 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents date incentive stock options first became exercisable. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 23:13 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 1,717 | $58.24 | $99,998.08 |
DisclosureSEC source: 0001567619-18-005885 · doc1.xml · nonDerivative · entry 4 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2018 Filed Nov 14, 2018 02:39 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Tax withholdingResMed Common Stock | 5,994 | $106.94 | $640,998.36 |
DisclosureSEC source: 0001567619-18-005911 · doc1.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,805 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. F3 · balance_after: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 09, 2018 Filed Nov 14, 2018 02:39 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Tax withholdingResMed Common Stock | 2,018 | $106.94 | $215,804.92 |
DisclosureSEC source: 0001567619-18-005911 · doc1.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,799 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 128.63 shares of ResMed stock purchased on October 31, 2018, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 23:13 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 1,199 | $106.94 | $128,221.06 |
DisclosureSEC source: 0001567619-18-005885 · doc1.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,036 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 23:13 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 1,083 | $106.94 | $115,816.02 |
DisclosureSEC source: 0001567619-18-005885 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,235 F2 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 23:13 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 854 | $106.94 | $91,326.76 |
DisclosureSEC source: 0001567619-18-005885 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,318 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 22:57 UTC |
Hollingshead JamesPresident, Americas
|
Tax withholdingResMed Common Stock | 2,398 | $106.94 | $256,442.12 |
DisclosureSEC source: 0001567619-18-005880 · doc1.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,275 F4 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 22:57 UTC |
Hollingshead JamesPresident, Americas
|
Tax withholdingResMed Common Stock | 1,125 | $106.94 | $120,307.50 |
DisclosureSEC source: 0001567619-18-005880 · doc1.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,673 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 22:57 UTC |
Hollingshead JamesPresident, Americas
|
Tax withholdingResMed Common Stock | 1,587 | $106.94 | $169,713.78 |
DisclosureSEC source: 0001567619-18-005880 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,798 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 80.49 shares of ResMed stock purchased on October 31, 2018, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 22:55 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 4,495 | $106.94 | $480,695.30 |
DisclosureSEC source: 0001567619-18-005879 · doc1.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,487 F4 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 22:55 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 8,092 | $106.94 | $865,358.48 |
DisclosureSEC source: 0001567619-18-005879 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,982 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 22:55 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 3,417 | $106.94 | $365,413.98 |
DisclosureSEC source: 0001567619-18-005879 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,074 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 199.72 shares of ResMed stock purchased on October 31, 2018, through the ResMed Employee Stock Purchase Plan Read SEC document |
| November 09, 2018 Filed Nov 17, 2018 01:08 UTC |
FARRELL PETER CDirector
|
Tax withholdingResMed Common Stock | 729 | $106.94 | $77,959.26 |
DisclosureSEC source: 0001567619-18-006569 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,167 F1 · shares: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2017. Read SEC document |
| November 05, 2018 Filed Nov 6, 2018 21:20 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,810 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001567619-18-005169 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 2,810 shares Expires 2019-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 05, 2018 Filed Nov 6, 2018 21:20 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 2,810 | $105.97 | $297,775.70 |
DisclosureSEC source: 0001567619-18-005169 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,172 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 05, 2018 Filed Nov 6, 2018 21:20 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 2,810 | $38.98 | $109,533.80 |
DisclosureSEC source: 0001567619-18-005169 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 131.84 shares of ResMed stock purchased on October 31, 2018, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 20:11 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 600 | $105.93 | $63,558.00 |
DisclosureSEC source: 0001567619-18-005009 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,304 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. F1 · price: The transaction was conducted under a Rule 10b5-1 Plan. F1 · balance_after: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.